Endologix, Inc. (ELGX) Posts Q3 EPS Loss of $0.09, Raises FY11 Sales Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ELGX Hot Sheet
Price: $0.22 --0%
Financial Fact:
Clinical and regulatory affairs: 3.76M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Clinical and regulatory affairs: 3.76M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Endologix, Inc. (NASDAQ: ELGX) reported Q3 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $22.3 million versus the consensus estimate of $20.14 million.
Endologix, Inc. sees FY2011 EPS of $-0.30-$-0.25. Endologix, Inc. sees FY2011 revenue of $82-$84 million, versus prior guidance of $79-$82 million.
Endologix, Inc. sees FY2011 EPS of $-0.30-$-0.25. Endologix, Inc. sees FY2011 revenue of $82-$84 million, versus prior guidance of $79-$82 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- Autoliv (ALV) Misses Q3 EPS by 7c
- Rithm Capital Corp. (RITM) Tops Q3 EPS by 6c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
